INO-4800
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | DNA |
| Clinical data | |
| Other names | Inovio COVID-19 Vaccine |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
INO-4800 is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.
Development[edit]
In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.[1][2] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.[3] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.[4]
Clinical research[edit]
Inovio is collaborating with Beijing Advaccine Biotechnology Co., a Chinese biotech firm,[2] in order to speed its acceptance by regulatory authorities in China, with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020.[5][6] Inovio has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful.[2] In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus.[5][7]
In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea, to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June.[8] The trial is funded by the Coalition for Epidemic Preparedness Innovations and supported by the Korea Centers for Disease Control and Prevention and the Korea National Institute of Health.[8]
References[edit]
- ^ Linnane C (8 March 2020). "Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April". MarketWatch. Retrieved 8 March 2020.
- ^ a b c Freeman M. "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". Los Angeles Times. Retrieved 17 February 2020.
- ^ "COVID-19 vaccine tracker (Select vaccine tab)". Milken Institute. 22 June 2020. Retrieved 23 June 2020. Lay summary.
- ^ Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov
- ^ a b Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. PMID 32273591.
- ^ Mazumdar T (30 January 2020). "Coronavirus: Scientists race to develop a vaccine". BBC News - Health. Retrieved 3 February 2020.
- ^ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.
- ^ a b "IVI and SNU partner to trial Inovio Covid-19 vaccine in Korea". Clinical Trials Arena. 5 June 2020. Retrieved 8 June 2020.
External links[edit]
 |
Scholia has a profile for INO-4800 (Q96695266). |
